Hologic Launches Novodiag® System for On-Demand Molecular Testing in Europe
5.10.2021 10:00:00 EEST | Business Wire | Press release
Hologic, Inc. (Nasdaq: HOLX) today announced its broad European launch of the Novodiag® system, a fully automated molecular diagnostic solution for on-demand testing of infectious diseases and antimicrobial resistance. The launch follows Hologic’s acquisition of Mobidiag Oy in June 2021 and will bring the benefits of the Novodiag system to a broader range of customers in Europe.
The Novodiag system combines real-time PCR and microarray capabilities. This enables multiple pathogens to be identified in a single sample, providing a simple and fast way to pinpoint patients most at risk with targeted and syndromic on-demand testing. Its CE-IVD test menu includes highly multiplexed on-demand assays detecting gastrointestinal infections and antibiotic resistance, as well as a targeted assay for the detection of SARS-CoV-2. A strong pipeline is also in development.
“Our acquisition of Mobidiag was aimed at strengthening our international diagnostics business. With the Hologic launch of the Novodiag system, we are delivering against this goal,” said Jan Verstreken, Group President, International at Hologic. “The addition of the Novodiag system to our diagnostic molecular scalable solutions portfolio will offer more customers in Europe a wider choice of solutions that meet their needs, from single patient rapid testing to population-level screening.”
Hologic’s current diagnostic offering is anchored by the Panther® System, a best-in-class, fully automated, sample-to-result platform designed to be used across laboratories of varying throughputs. The Novodiag system is a high multiplex technology that is precision-engineered for simplicity, accuracy and affordability across a broad and growing menu of high- and low-plex assays. It complements the Panther System, along with Panther Scalable Solutions, and expands Hologic’s offering, allowing the Company to meet customers’ growing diagnostic testing needs from small to the largest laboratories.
Tuomas Tenkanen, CEO, Mobidiag, a Hologic company said, “Mobidiag is already realizing the benefits of being part of the Hologic family, and today’s launch will allow Novodiag to reach a far broader customer market faster, delivering the benefits of an on-demand system that offers ease of use, high multiplex capability and a rapid turnaround time.”
For more information visit https://www.hologic.com/hologic-products/novodiag-system.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.
Hologic, Mobidiag, Novodiag, Panther and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
Forward Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about launching the Novodiag system and related assays. There can be no assurance that these products will achieve the benefits described herein, that they will be commercially successful or achieve any expected level of sales, or that these efforts will be successful, benefit the Company and its stockholders, or improve over time. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any changes in expectations or events, conditions or circumstances on which any such data or statements are based.
SOURCE: Hologic, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005411/en/
Contact information
Hologic
Investor Contact:
Michael Watts
+1 858.410.8588
michael.watts@hologic.com
Media Contact:
Jane Mazur
+1 508.263.8764 (direct)
+1 585.355.5978 (mobile)
jane.mazur@hologic.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azul Addresses the Java Runtime Security Blind Spot Autonomous AI Can Now Exploit17.6.2026 16:00:00 EEST | Press release
Azul, the trusted leader in enterprise Java for today’s AI and cloud-first world, today launched a free JVM vulnerability risk assessment to address the blind spot that autonomous AI exploitation tools are increasingly able to find. With mean time to exploit (MTTE) collapsing from months to days or hours, the unmanaged Java estate has become an urgent enterprise security vulnerability. Azul’s assessment gives DevOps and SecOps teams complete visibility into the hidden risks embedded in the runtime of their Java estate before threat actors get there first, and is designed to complement the broader security, licensing and compliance solutions and services delivered by Azul’s trusted partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617352753/en/ Azul's JVM Vulnerability Risk Assessment dashboard. The Threat Landscape Has Transformed For most of Java’s enterprise history, a sophisticated exploit required a sophisticat
Hologic’s New Sustainability Report Marks 40 Years of Impact17.6.2026 16:00:00 EEST | Press release
Hologic, Inc., a global leader in women’s health, today released its 2025 Sustainability Report. The new report coincides with Hologic’s 40th anniversary and underscores how the company’s longstanding purpose — to enable healthier lives for women everywhere, every day — continues to drive progress for patients, communities and the planet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617160174/en/ Hologic 2025 Sustainability Report “We have always firmly believed that our success as a company is fundamentally tied to our ability and commitment to help women worldwide live healthier lives,” said Sharon Vidal, Chief Sustainability Officer at Hologic. “Together with our customers and partners, we’re taking measurable steps to increase global access to innovative medical technologies while pursuing a more sustainable and equitable future for all.” Hologic’s Sustainability Report details progress on environmental sustainabili
Fortegra Strengthens Actuarial Leadership with Appointment of Anthony Katz as SVP, Reserving17.6.2026 16:00:00 EEST | Press release
The Fortegra Group, Inc., a global specialty insurer, today announced the appointment of Anthony Katz as Senior Vice President, Reserving. Mr. Katz will lead Fortegra’s team of professional actuaries, with responsibility for reserving, credit insurance, statistical reporting, and key initiatives including IFRS 17. “Anthony brings more than 30 years of actuarial expertise and a genuine commitment to building the capabilities our distribution partners depend on,” said Rick Kahlbaugh, Chief Executive Officer at Fortegra. “His background across reserving, actuarial transformation, and international markets will be instrumental as we continue to support our distribution partners.” A credentialed actuary holding FCAS, FSA, and MAAA designations, Mr. Katz brings more than 30 years of experience across reserving, pricing, and actuarial transformation. He has held senior leadership roles at ToaRe, Everest Re, Arch Insurance, Ernst & Young, and ACE, and most recently served as an independent con
Hitachi Expands Its Work With OpenAI to Accelerate AI-Driven Modernization and Cybersecurity17.6.2026 16:00:00 EEST | Press release
Hitachi, Ltd. (TSE:6501, "Hitachi") today announced that it will expand its work with OpenAI*1 to accelerate AI-driven modernization and cybersecurity. The work combines OpenAI’s frontier AI technology with Hitachi’s domain expertise and know-how in supporting mission-critical systems and social infrastructure to accelerate AI transformation (AX) for customers and society. Working together, the two companies’ FDE teams will leverage OpenAI’s AI agent “Codex” to analyze the source code of mission-critical legacy systems and work to establish an AI-driven modernization approach that supports safe migration through enhanced visibility into system design. Based on this approach, Hitachi aims to develop solutions to support the modernization of core systems and to roll them out sequentially across a wide range of industries, starting with financial institutions. Hitachi also plans to gain access to OpenAI’s AI models for cybersecurity through OpenAI’s “Trusted Access for Cyber (TAC)”.*2 As
Laprophan Completes the Acquisition of Rivopharm, Accelerating Its International Expansion Strategy17.6.2026 15:39:00 EEST | Press release
Laprophan Group, the pioneer and one of Morocco's leading pharmaceutical groups, today announced the successful completion of the acquisition of a controlling stake in Rivopharm, a Switzerland-based pharmaceutical company specialized in specialty medicines, dossier development, complex formulations and value-added pharmaceutical solutions, and operating its own industrial manufacturing site. The financial terms of the transaction were not disclosed. Rivopharm generates annual revenue of approximately US$100 million. The acquisition represents a transformational milestone in Laprophan's development and marks the Group's first acquisition in Europe. The transaction significantly strengthens Laprophan's European footprint and accelerates its ambition to build a differentiated international pharmaceutical platform spanning Europe, Africa, the Middle East and selected global markets. The acquisition was carried out through Europhan, Laprophan's Luxembourg-based European platform, reinforcin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom